• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

VIVUS, Inc.

NASDAQ:VVUS

$24.59 -$0.18 (-0.73%)

REAL-TIME: Last trade at

Outlooks for Pfizer, Arena and Onyx Following Busy May

VIVUS option implied volatility low

BioCentury to host a conference

Mulling Arena Pharma's Future With Obesity Drug on Approval Path

Today's Hot Stocks: Micron, Sara Lee, Nordstrom, Best Buy, Suncor Energy, and VIVUS

Anti-Obesity Drugs a Hot Topic in the Biotech Industry

Anti-Obesity Drugs a Hot Topic in the Biotech Industry

24/7 Wall St. Closing Bell

Jefferies Upgrades Arena Pharmaceuticals to 'Buy'

Leerink Still Sees VIVUS's (VVUS) Qnexa as 'Obesity Therapy of Choice'

Arena Soars After Weight-Loss Pill Recommended for Approval by FDA Staff

Stocks with implied volatility movement; NTAP VVUS

Arena's Weight Loss Drug Receives FDA Advisory Panel Recommendation For Approval

VIVUS shares down 37c, or 1.63%, to $22.38

Battle to Fight Obesity

Vivus Will Plummet If Qnexa Fails

Vertex Leads A Big Week For Biotechs

5 Biotech Stocks To Buy Now For Gains In 2013

Biotechs Bucking The Dendreon Trap & Curse (DNDN, VRTX, VVUS, ARNA, ALNY, AMGN, SVNT)

Diet Pill Maker Arena Pharmaceuticals' Stock Jumps Ahead of US Review

Needham & Company Reiterates a 'Buy' on Vivus (VVUS); Expect Approval of Qnexa by the PDUFA Date

Electronic Arts, Mako Surgical, Vivus, Wynn: U.S. Equity Preview

Vivus' ED Drug Gets Green Signal - Analyst Blog

Vivus' ED Drug Gets Green Signal

Vivus, Inc. (VVUS) Misses Q1 EPS by 7c

VIVUS reports Q1 EPS (20c), consensus (14c)

6 Best Biotech Stocks With More Upside Potential

The 8 Earnings Reports Shaping The Week Ahead (DNDN, EA, RAX, DIS, CSCO, M, NUAN)

VIVUS to Present at Three Investor Conferences in May

Catalysts Move Drug and Medtech Stocks: Michael Hay and Jocelyn August

Results Of My Options Strategy For Vivus

VIVUS Announces Date of First Quarter 2012 Financial Results and Conference Call

VIVUS Announces Date of First Quarter 2012 Financial Results and Conference Call

Novo Nordisk Losing Its Sugar High?

Vivus Wins FDA Approval

Vivus in talks to out-license ED drug Stendra

PennyStocksGuru.net Issues Alert On Stocks To Watch For Monday, April 30th, 2012: SunPeaks Ventures (SNPK.OB), SEFE Incorporated (SEFE.OB), Entertainment Gaming Asia, Abaxis Inc and VIVUS

VIVUS may obtain about $3 per share for drug, says JMP Securities

StockReports.net Issues Alert On Stocks To Watch For Monday, April 30th, 2012: SunPeaks Ventures, SEFE Incorporated, Entertainment Gaming Asia, Abaxis and VIVUS.

FDA Backs New Rival For Viagra

See More Articles...